Abstract
RapifortⓇwipes 2.5％is the first wipe pharmaceutical form approved in Japan and is a partially modified formulation of QbrexzaⓇdeveloped by Dermira, Inc. in January 2022. The wipe is applied to both axillae once a day to control sweating of primary axillary hyperhidrosis. The drug solution impregnated into a wipe is changed to classify it as a non-hazardous substance under the Fire Service Act in Japan. The wipe is selected for reactivity with the drug solution and water absorbency, and the pouch is designed with the multiple-layer structure to ensure drug quality. This article describes the details of the formulation change and packaging design of the wipe and the clinical trial results.
